Explore
Validate
Learn50-8277-41
antibody from Invitrogen Antibodies
Targeting: IL27
IL-27, IL-27A, IL27A, IL27p28, IL30, MGC71873, p28
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 50-8277-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- IL-27 p28 Monoclonal Antibody (3D1p28), eFluor™ 660, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- Description: This 3D1p28 monoclonal antibody reacts with the human p28 subunit of IL-27. Interleukin-27 (IL-27) is a member of the IL-12 family, a subgroup of the IL-6 family of cytokines. It is a heterodimer of the subunits EBI3 (Epstein-Barr Virus Induced Gene 3), which is homologous to the p40 subunit shared by IL-12 and IL-23, and p28 (IL-30), which is homologous to p35. IL-27 is produced by activated dendritic cells and macrophages in response to TLR ligands and inflammatory cytokines. IL-27 has been shown to have both pro-inflammatory and anti-inflammatory effects. It influences the commitment of CD4+ T-cells toward the Th1 lineage by inducing the expression of the transcription factor T-bet and the upregulation of IL-12R beta2. Its anti-inflammatory functions include the suppression of Th2 and Th17 proliferation and differentiation.
- Antibody clone number
- 3D1p28
- Concentration
- 5 µL/Test
Submitted references A role for IL-27p28 as an antagonist of gp130-mediated signaling.
Advances in understanding the anti-inflammatory properties of IL-27.
Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism.
Stumhofer JS, Tait ED, Quinn WJ 3rd, Hosken N, Spudy B, Goenka R, Fielding CA, O'Hara AC, Chen Y, Jones ML, Saris CJ, Rose-John S, Cua DJ, Jones SA, Elloso MM, Grötzinger J, Cancro MP, Levin SD, Hunter CA
Nature immunology 2010 Dec;11(12):1119-26
Nature immunology 2010 Dec;11(12):1119-26
Advances in understanding the anti-inflammatory properties of IL-27.
Stumhofer JS, Hunter CA
Immunology letters 2008 May 15;117(2):123-30
Immunology letters 2008 May 15;117(2):123-30
Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism.
Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, Yoshimura A, Yoshida H
Journal of immunology (Baltimore, Md. : 1950) 2006 Oct 15;177(8):5377-85
Journal of immunology (Baltimore, Md. : 1950) 2006 Oct 15;177(8):5377-85
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Normal human peripheral blood cells unstimulated (left) or stimulated with Human IFN gamma Recombinant Protein (Product # 14-8319-80), LPS, and the Imidazoquinoline, R848, in the presence of Protein Transport Inhibitor Cocktail (Product # 00-4980-03) and stained intracellularly with Anti-Human IL-27 EBI3 PE (Product # 12-7358-42) and Anti-Human IL-27 p28 eFluor® 660. Cells in the monocyte gate were used for analysis.
